Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab‐Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results

LESSONS LEARNED. Despite the compelling preclinical rationale of evaluating the genetically engineered heparin derivative, necuparanib, combined with standard therapy in metastatic pancreas adenocarcinoma, the results were ultimately disappointing. Safety was documented, although dose escalation was...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncologist
Auteurs principaux: O'Reilly, Eileen M., Roach, James, Miller, Paul, Yu, Kenneth H., Tjan, Catherine, Rosano, Molly, Krause, Silva, Avery, William, Wolf, Julie, Flaherty, Keith, Nix, Darrell, Ryan, David P.
Format: Artigo
Langue:Inglês
Publié: AlphaMed Press 2017
Sujets:
Clinical Trial Results
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5728039/
https://ncbi.nlm.nih.gov/pubmed/29158367
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0472
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires